Strides Shasun gets USFDA’s nod for Ranitidine Tablets

24 Aug 2016 Evaluate

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Ranitidine Tablets USP, 150 mg and 300 mg. Ranitidine tablet is the first integrated product approval where the API and formulations will be manufactured at erstwhile Shasun Pharmaceutical's Cuddalore and Pondicherry facilities respectively.

The US market for Ranitidine Tablets USP, 150 mg and 300 mg is around $125 Million. The product to be launched immediately will be marketed by Strides Pharma Inc in the US Market.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

913.55 11.20 (1.24%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×